GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

A pat­ent dis­pute between GSK sub­si­di­ary ViiV Health­care and Colom­bian reg­u­lat­ors is not cur­rently before the Inter­na­tional Centre for Set­tle­ment of Invest­ment Dis­putes in Wash­ing­ton ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

From December 22 to January 2, people on Grindr across the globe can experience Roam, a popular new feature, free of charge.

The PILLAR study found that a majority of men who have sex with men and transgender men chose long-acting cabotegravir ...

The population most affected by HIV has changed in recent years, and public health messaging may not be reaching the ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

大姐肺癌脑转移，惊现3公分大肿瘤！速锐刀治疗后直呼：好神奇 ...